IBRX icon

ImmunityBio

126 hedge funds and large institutions have $196M invested in ImmunityBio in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 50 increasing their positions, 26 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more capital invested

Capital invested by funds: $ → $

more ownership

Funds ownership:

less funds holding

Funds holding:

19% less call options, than puts

Call options by funds: $3.06M | Put options by funds: $3.79M

22% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 23

Holders
126
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$3.06M
Puts
$3.79M
Net Calls
Net Calls Change

Top Buyers

1 +$23.8M
2 +$2.77M
3 +$1.99M
4
Citigroup
Citigroup
New York
+$1.78M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.73M
Name Holding Trade Value Shares
Change
Change in
Stake
51
$279K
52
$277K
53
$274K
54
$266K
55
$256K
56
$245K
57
$238K
58
$229K
59
$219K
60
$212K
61
$208K
62
$207K
63
$197K
64
$193K
65
$193K
66
$176K
67
$174K
68
$161K
69
$156K
70
$150K
71
$150K
72
$144K
73
$142K
74
$138K
75
$125K